1. Brody SL, Crystal RG. Adenovirus-mediated in vivo gene transfer. Ann N Y Acad Sci 1994; 716:90-101.

2. Bramson JL, Graham FL, Gauldie J. The use of adenoviral vectors for gene therapy and gene transfer in vivo. Curr Opin Biotechnol 1995; 6:590-595.

3. Trapnell BC, Gorziglia M. Gene therapy using adenoviral vectors. Curr Opin Biotechnol 1994; 5:617-625.

4. Kozarsky KF, Wilson JM. Gene therapy: Adenovirus vectors. Curr Opin Genet Dev 1993; 3:499-503.

5. Hackett NR, Kaminsky SM, Sondhi D, Crystal RG. Antivector and antitransgene host responses in gene therapy. Curr Opin Mol Ther 2000; 2:376-382.

6. Crystal RG. Transfer of genes to humans: Early lessons and obstacles to success. Science 1995; 270:404-410.

7. Horwitz MS. Fields Virology. Fields BN, Knipe DM, Howley PM, Eds. Philadelphia: Lippincott-Raven Publishers, Inc., 1996:2149.

8. Bailey A, Mautner V. Phylogenetic relationships among adenovirus serotypes. Virology 1994; 205:438-452.

9. Ginsberg HS, Prince GA. The molecular basis of adenovirus pathogenesis. Infect Agents Dis 1994; 3:1-8.

10. Shenk T. Fields Virology. Fields BN, Knipe DM, Howley PM, Eds. Philadelphia: Lippincott-Raven Publishers, Inc., 1996: 2111.

11. Athappilly FK, Murali R, Rux JJ, Cai Z, Burnett RM. The refined crystal structure of hexon, the major coat protein of adenovirus type 2, at 2.9 A resolution. J Mol Biol 1994; 242: 430-455.

12. Crawford-Miksza L, Schnurr DP. Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues. J Virol 1996; 70:1836-1844.

13. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275:1320-1323.

14. Roelvink PW, Lizonova A, Lee JG, Li Y, Bergelson JM, Finberg RW, Brough DE, Kovesdi I, Wickham TJ. The coxsackie-virus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J Virol 1998; 72:7909-7915.

15. Wickham TJ, Filardo EJ, Cheresh DA, Nemerow GR. Integrin alpha v beta 5 selectively promotes adenovirus mediated cell membrane permeabilization. J Cell Biol 1994; 127:257-264.

16. Mathias P, Wickham T, Moore M, Nemerow G. Multiple ade-novirus serotypes use alpha v integrins for infection. J Virol 1994; 68:6811-6814.

17. Wickham TJ, Carrion ME, Kovesdi I. Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifs. Gene Ther 1995; 2:750-756.

18. Wang K, Huang S, Kapoor-Munshi A, Nemerow G. Adenovirus internalization and infection require dynamin. J Virol 1998; 72:3455-3458.

19. Leopold PL, Kreitzer G, Miyazawa N, Rempel S, Pfister KK, Rodriguez-Boulan E, Crystal RG. Dynein- and microtubule-mediated translocation of adenovirus serotype 5 occurs after endosomal lysis. Hum Gene Ther 2000; 11:151-165.

20. Trotman LC, Mosberger N, Fornerod M, Stidwill RP, Greber UF. Import of adenovirus DNA involves the nuclear pore complex receptor CAN/Nup214 and histone H1. Nat Cell Biol 2001; 3:1092-1100.

21. Leopold PL, Ferris B, Grinberg I, Worgall S, Hackett NR, Crystal RG. Fluorescent virions: Dynamic tracking of the pathway of adenoviral gene transfer vectors in living cells. Hum Gene Ther 1998; 9:367-378.

22. Wold WS, Tollefson AE, Hermiston TW. E3 transcription unit of adenovirus. Curr Top Microbiol Immunol 1995; 199: 237-274.

23. Shisler J, Yang C, Walter B, Ware CF, Gooding LR. The adenovirus E3-10.4K/14.5K complex mediates loss of cell surface Fas (CD95) and resistance to Fas-induced apoptosis. J Virol 1997; 71:8299-8306.

24. Puvion-Dutilleul F, Puvion E. Sites of transcription of adeno-virus type 5 genomes in relation to early viral DNA replication in infected HeLa cells. A high resolution in situ hybridization and autoradiographical study. Biol Cell 1991; 71:135-147.

25. Alemany R, Dai Y, Lou YC, Sethi E, Prokopenko E, Josephs SF, Zhang WW. Complementation of helper-dependent adenoviral vectors: Size effects and titer fluctuations. J Virol Methods 1997; 68:147-159.

26. Bett AJ, Prevec L, Graham FL. Packaging capacity and stability of human adenovirus type 5 vectors. J Virol 1993; 67: 5911-5921.

27. Graham FL, Prevec L. Methods for construction of adenovirus vectors. Mol Biotechnol 1995; 3:207-220.

28. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977; 36:59-74.

29. Louis N, Evelegh C, Graham FL. Cloning and sequencing of the cellular-viral junctions from the human adenovirus type 5 transformed 293 cell line. Virology 1997; 233:423-429.

30. Rosenfeld MA, Yoshimura K, Trapnell BC, Yoneyama K, Rosenthal ER, Dalemans W, Fukayama M, Bargon J, Stier LE, Stratford-Perricaudet L, Perricaudet M, Guggino WB, Pavirani A, Lecocq J-P, Crystal RG. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 1992; 68:143-155.

31. He TC, Zhou S, Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95:2509-2514.

32. Hehir KM, Armentano D, Cardoza LM, Choquette TL, Berthelette PB, White GA, Couture LA, Everton MB, Keegan J, Martin JM, Pratt DA, Smith MP, Smith AE, Wadsworth SC. Molecular characterization of replication-competent variants of adenovirus vectors and genome modifications to prevent their occurrence. J Virol 1996; 70:8459-8467.

33. Mittereder N, March KL, Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 1996; 70:7498-7509.

34. Setoguchi Y, Jaffe HA, Chu CS, Crystal RG. Intraperitoneal in vivo gene therapy to deliver alpha 1-antitrypsin to the systemic circulation. Am J Respir Cell Mol Biol 1994; 10:369-377.

35. Mittal SK, Bett AJ, Prevec L, Graham FL. Foreign gene expression by human adenovirus type 5-based vectors studied using firefly luciferase and bacterial beta-galactosidase genes as reporters. Virology 1995; 210:226-230.

36. Kaner RJ, Worgall S, Leopold PL, Stolze E, Milano E, Hidaka C, Ramalingam R, Hackett NR, Singh R, Bergelson J, Finberg R, Falck-Pedersen E, Crystal RG. Modification of the genetic program of human alveolar macrophages by adenovirus vectors in vitro is feasible but inefficient, limited in part by the low level of expression of the coxsackie/adenovirus receptor. Am J Respir Cell Mol Biol 1999; 20:361-370.

37. Leon RP, Hedlund T, Meech SJ, Li S, Schaack J, Hunger SP, Duke RC, Gregori J. Adenoviral-mediated gene transfer in lymphocytes. Proc Natl Acad Sci USA 1998; 95: 13159-13164.

38. Wickham TJ, Lee GM, Titus JA, Sconocchia G, Bakacs T, Kovesdi I, Segal DM. Targeted adenovirus-mediated gene delivery to T cells via CD3. J Virol 1997; 71:7663-7669.

39. Hidaka C, Milano E, Leopold PL, Bergelson JM, Hackett NR, Finberg RW, Wickham TJ, Kovesdi I, Roelvink P, Crystal RG. CAR-dependent and CAR-independent pathways of ade-novirus vector-mediated gene transfer and expression in human fibroblasts. J Clin Invest 1999; 103:579-587.

40. Arbuthnot PB, Bralet MP, Le Jossic C, Dedieu JF, Perricaudet M, Brechot C, Ferry N. In vitro and in vivo hepatoma cell-specific expression of a gene transferred with an adenoviral vector. Hum Gene Ther 1996; 20:1503-1514.

41. Huang H, Chen SH, Kosai K, Finegold MJ, Woo SL. Gene therapy for hepatocellular carcinoma: Long-term remission of primary and metastatic tumors in mice by interleukin-2 gene therapy in vivo. Gene Ther 1996; 3:980-987.

42. Kock H, Harris MP, Anderson SC, Machemer T, Hancock W, Sutjipto S, Wills KN, Gregory RJ, Shepard HM, Westphal M, Maneval DC. Adenovirus-mediated p53 gene transfer suppresses growth of human glioblastoma cells in vitro and in vivo. Int J Cancer 1996; 67:808-815.

43. Prince HM, Dessureault S, Gallinger S, Krajden M, Sutherland DR, Addison C, Zhang Y, Graham FL, Stewart AK. Efficient adenovirus-mediated gene expression in malignant human plasma cells: Relative lymphoid cell resistance. Exp Hematol 1998; 26:27-36.

44. Wattel E, Vanrumbeke M, Abina MA, Cambier N, Preud-homme C, Haddada H, Fenaux P. Differential efficacy of ade-noviral mediated gene transfer into cells from hematological cell lines and fresh hematological malignancies. Leukemia 1996; 10:171-174.

45. Bonnekoh B, Greenhalgh DA, Bundman DS, Eckhardt JN, Longley MA, Chen SH, Woo SL, Roop DR. Inhibition of melanoma growth by adenoviral-mediated HSV thymidine ki-nase gene transfer in vivo. J Invest Dermatol 1995; 104: 313-317.

46. Hall SJ, Mutchnik SE, Chen SH, Woo SL, Thompson TC. Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer. Int J Cancer 1997; 70:183-187.

47. Behbakht K, Benjamin I, Chiu HC, Eck SL, Van Deerlin PG, Rubin SC, Boyd J. Adenovirus-mediated gene therapy ofovar-ian cancer in a mouse model. Am J Obstet Gynecol 1996; 175: 1260-1265.

48. Tong XW, Block A, Chen SH, Contant CF, Agoulnik I, Blankenburg K, Kaufman RH, Woo SL, Kieback DG. In vivo gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration. Gyn-ecol Oncol 1996; 61:175-179.

49. Christ M, Lusky M, Stoeckel F, Dreyer D, Dieterle A, Michou AI, Pavirani A, Mehtali M. Gene therapy with recombinant adenovirus vectors: Evaluation of the host immune response. Immunol Lett 1997; 57:19-25.

50. Gao GP, Yang Y, Wilson JM. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol 1996; 70:8934-8943.

51. Gorziglia MI, Kadan MJ, Yei S, Lim J, Lee GM, Luthra R, Trapnell BC. Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy. J Virol 1996; 70:4173-4178.

52. Rosenfeld MA, Siegfried W, Yoshimura K, Yoneyama K, Fukayama M, Stier LE, Paakko PK, Gilardi P, Stratford-Perri-caudet LD, Perricaudet M, Jallat S, Pavirani A, Lecocq J-P, Crystal RG. Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo. Science 1991; 252:431-434.

53. Zabner J, Petersen DM, Puga AP, Graham SM, Couture LA, Keyes LD, Lukason MJ, George JA, Gregory RJ, Smith AE. Safety and efficacy of repetitive adenovirus-mediated transfer of CFTR cDNA to airway epithelia of primates and cotton rats. Nat Genet 1994; 6:75-83.

54. Yei S, Mittereder N, Wert S, Whitsett JA, Wilmott RW, Trap-nell BC. In vivo evaluation of the safety of adenovirus-me-diated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lung. Hum Gene Ther 1994; 5:731-744.

55. Mastrangeli A, Danel C, Rosenfeld MA, Stratford-Perricaudet L, Perricaudet M, Pavirani A, Lecocq JP, Crystal RG. Diversity of airway epithelial cell targets for in vivo recombinant adenovirus-mediated gene transfer. J Clin Invest 1993; 91: 225-234.

56. Peeters MJ, Patijn GA, Lieber A, Meuse L, Kay MA. Adenovi-rus-mediated hepatic gene transfer in mice: Comparison of intravascular and biliary administration. Hum Gene Ther 1996; 7:1693-1699.

57. Hackett NR, El Sawy T, Lee LY, Silva I, O'Leary J, Rosengart TK, Crystal RG. Use of quantitative TaqMan real-time PCR to track the time-dependent distribution of gene transfer vectors in vivo. Mol Ther 2000; 2:649-656.

58. Huard J, Lochmuller H, Acsadi G, Jani A, Massie B, Karpati G. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther 1995; 2:107-115.

59. Zhu G, Nicolson AG, Zheng XX, Strom TB, Sukhatme VP. Adenovirus-mediated beta-galactosidase gene delivery to the liver leads to protein deposition in kidney glomeruli. Kidney Int 1997; 52:992-999.

60. Raper SE, De Matteo RP. Adenovirus-mediated in vivo gene transfer and expression in normal rat pancreas. Pancreas 1996; 12:401-410.

61. Bajocchi G, Feldman SH, Crystal RG, Mastrangeli A. Direct in vivo gene transfer to ependymal cells in the central nervous system using recombinant adenovirus vectors. Nat Genet 1993; 3:229-234.

62. Xing Z, Ohkawara Y, Jordana M, Graham FL, Gauldie J. Ade-noviral vector-mediated interleukin-10 expression in vivo: Intramuscular gene transfer inhibits cytokine responses in endo-toxemia. Gene Ther 1997; 4:140-149.

63. Barkats M, Bilang-Bleuel A, Buc-Caron MH, Castel-Barthe MN, Corti O, Finiels F, Horellou P, Revah F, Sabate O, Mallet J. Adenovirus in the brain: Recent advances of gene therapy for neurodegenerative diseases. Prog Neurobiol 1998; 55: 333-341.

64. Mack CA, Patel SR, Schwarz EA, Zanzonico P, Hahn RT, Ilercil A, Devereux RB, Goldsmith SJ, Christian TF, Sanborn TA, Kovesdi I, Hackett N, Isom OW, Crystal RG, Rosengart TK. Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J Thorac Cardiovasc Surg 1998; 115:168-176.

65. French BA, Mazur W, Ali NM, Geske RS, Finnigan JP, Rodgers GP, Roberts R, Raizner AE. Percutaneous transluminal in vivo gene transfer by recombinant adenovirus in normal porcine coronary arteries, atherosclerotic arteries, and two models of coronary restenosis. Circulation 1994; 90:2402-2413.

66. Parr MJ, Wen PY, Schaub M, Khoury SJ, Sayegh MH, Fine HA. Immune parameters affecting adenoviral vector gene therapy in the brain. J Neurovirol 1998; 4:194-203.

67. Di Polo A, Aigner LJ, Dunn RJ, Bray GM, Aguayo AJ. Prolonged delivery of brain-derived neurotrophic factor by adeno-virus-infected Muller cells temporarily rescues injured retinal ganglion cells. Proc Natl Acad Sci USA 1998; 95:3978-3983.

68. Byrnes AP, MacLaren RE, Charlton HM. Immunological instability of persistent adenovirus vectors in the brain: Peripheral exposure to vector leads to renewed inflammation, reduced gene expression, and demyelination. J Neurosci 1996; 16:3045-3055.

69. Worgall S, Leopold PL, Wolff G, Ferris B, Van Roijen N, Crystal RG. Role of alveolar macrophages in rapid elimination of adenovirus vectors administered to the epithelial surface of the respiratory tract. Hum Gene Ther 1997; 8:1675-1684.

70. Wolff G, Worgall S, van Rooijen N, Song WR, Harvey BG, Crystal RG. Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ. J Virol 1997; 71:624-629.

71. Mack CA, Song WR, Carpenter H, Wickham TJ, Kovesdi I, Harvey BG, Magovern CJ, Isom OW, Rosengart T, Falck-Pedersen E, Hackett NR, Crystal RG, Mastrangeli A. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum Gene Ther 1997; 8:99-109.

72. Chirmule N, Hughes JV, Gao GP, Raper SE, Wilson JM. Role of E4 in eliciting CD4 T-cell and B-cell responses to adenovirus vectors delivered to murine and nonhuman primate lungs. J Virol 1998; 72:6138-6145.

73. Yang Y, Su Q, Wilson JM. Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs. J Virol 1996; 70:7209-7212.

74. Gahery-Segard H, Juillard V, Gaston J, Lengagne R, Pavirani A, Boulanger P, Guillet JG. Humoral immune response to the capsid components of recombinant adenoviruses: Routes of immunization modulate virus-induced Ig subclass shifts. Eur J Immunol 1997; 27:653-659.

75. Ilan Y, Jona VK, Sengupta K, Davidson A, Horwitz MS, Roy-Chowdhury N, Roy-Chowdhury J. Transient immunosuppression with FK506 permits long-term expression of therapeutic genes introduced into the liver using recombinant adenovir-uses in the rat. Hepatology 1997; 26:949-956.

76. Song W, Kong HL, Traktman P, Crystal RG. Cytotoxic T lymphocyte responses to proteins encoded by heterologous transgenes transferred in vivo by adenoviral vectors. Hum Gene Ther 1997; 8:1207-1217.

77. Tripathy SK, Black HB, Goldwasser E, Leiden JM. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med 1996; 2:545-550.

78. Zhang Y, Chirmule N, Gao GP, Qian R, Croyle M, Joshi B, Tazelaar J, Wilson JM. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther 2001; 3:697-707.

79. Worgall S, Wolff G, Falck-Pedersen E, Crystal RG. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther 1997; 8:37-44.

80. Dai Y, Schwarz EM, Gu D, Zhang WW, Sarvetnick N, Verma IM. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 1995; 92:1401-1405.

81. Michou AI, Santoro L, Christ M, Julliard V, Pavirani A, Meh-tali M. Adenovirus-mediated gene transfer: Influence of transgene, mouse strain and type of immune response on persistence of transgene expression. Gene Ther 1997; 4:473-482.

82. Sullivan DE, Dash S, Du H, Hiramatsu N, Aydin F, Kolls J, Blanchard J, Baskin G, Gerber MA. Liver-directed gene transfer in non-human primates. Hum Gene Ther 1997; 8: 1195-1206.

83. Geddes BJ, Harding TC, Hughes DS, Byrnes AP, Lightman SL, Conde G, Uney JB. Persistent transgene expression in the hypothalamus following stereotaxic delivery of a recombinant adenovirus: Suppression of the immune response with cyclosporin. Endocrinology 1996; 137:5166-5169.

84. Elshami AA, Kucharczuk JC, Sterman DH, Smythe WR, Hwang HC, Amin KM, Litzky LA, Albelda SM, Kaiser LR. The role of immunosuppression in the efficacy of cancer gene therapy using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann Surg 1995; 222:298-307.

85. Cassivi SD, Liu M, Boehler A, Tanswell AK, Slutsky AS, Keshavjee S, Todd STRJ. Transgene expression after adenovi-rus-mediated retransfection of rat lungs is increased and pro longed by transplant immunosuppression. J Thorac Cardiovasc Surg 1999; 117:1-7.

86. Scaria A, George JA, Gregory RJ, Noelle RJ, Wadsworth SC, Smith AE, Kaplan JM. Antibody to CD40 ligand inhibits both humoral and cellular immune responses to adenoviral vectors and facilitates repeated administration to mouse airway. Gene Ther 1997; 4:611-617.

87. Yang Y, Su Q, Grewal IS, Schilz R, Flavell RA, Wilson JM. Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. J Virol 1996; 70:6370-6377.

88. Jooss K, Turka LA, Wilson JM. Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig. Gene Ther 1998; 5:309-319.

89. Guibinga GH, Lochmuller H, Massie B, Nalbantoglu J, Kar-pati G, Petrof BJ. Combinatorial blockade of calcineurin and CD28 signaling facilitates primary and secondary therapeutic gene transfer by adenovirus vectors in dystrophic (mdx) mouse muscles. J Virol 1998; 72:4601-4609.

90. Yang Y, Nunes FA, Berencsi K, Gonczol E, Engelhardt JF, Wilson JM. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet 1994; 7:362-369.

91. Engelhardt JF, Litzky L, Wilson JM. Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a. Hum Gene Ther 1994; 5:1217-1229.

92. Engelhardt JF, Ye X, Doranz B, Wilson JM. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 1994; 91:6196-6200.

93. Brough DE, Lizonova A, Hsu C, Kulesa VA, Kovesdi I. A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J Virol 1996; 70:6497-6501.

94. Brough DE, Hsu C, Kulesa VA, Lee GM, Cantolupo LJ, Lizonova A, Kovesdi I. Activation of transgene expression by early region 4 is responsible for a high level of persistent transgene expression from adenovirus vectors in vivo. J Virol 1997; 71: 9206-9213.

95. Dedieu JF, Vigne E, Torrent C, Jullien C, Mahfouz I, Caillaud JM, Aubailly N, Orsini C, Guillaume JM, Opolon P, Delaere P, Perricaudet M, Yeh P. Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses. J Virol 1997; 71:4626-4637.

96. Wang Q, Greenburg G, Bunch D, Farson D, Finer MH. Persistent transgene expression in mouse liver following in vivo gene transfer with a delta E1/delta E4 adenovirus vector. Gene Ther 1997; 4:393-400.

97. Armentano D, Zabner J, Sacks C, Sookdeo CC, Smith MP, George JA, Wadsworth SC, Smith AE, Gregory RJ. Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. J Virol 1997; 71:2408-2416.

98. Schowalter DB, Tubb JC, Liu M, Wilson CB, Kay MA. Heterologous expression of adenovirus E3-gp19K in an E1a-deleted adenovirus vector inhibits MHC I expression in vitro, but does not prolong transgene expression in vivo. Gene Ther 1997; 4: 351-360.

99. Lee MG, Abina MA, Haddada H, Perricaudet M. The constitutive expression of the immunomodulatory gp19k protein in E1~, E3~ adenoviral vectors strongly reduces the host cyto-toxic T cell response against the vector. Gene Ther 1995; 2: 256-262.

100. Bruder JT, Jie T, McVey DL, Kovesdi I. Expression of gp19K increases the persistence of transgene expression from an adenovirus vector in the mouse lung and liver. J Virol 1997; 71: 7623-7628.

101. Ilan Y, Droguett G, Chowdhury NR, Li Y, Sengupta K, Thum-mala NR, Davidson A, Chowdhury JR, Horwitz MS. Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. Proc Natl Acad Sci USA 1997; 94:2587-2592.

102. Poller W, Schneider-Rasp S, Liebert U, Merklein F, Thal-heimer P, Haack A, Schwaab R, Schmitt C, Brackmann HH. Stabilization of transgene expression by incorporation of E3 region genes into an adenoviral factor IX vector and by transient anti-CD4 treatment of the host. Gene Ther 1996; 3: 521-530.

103. Gilbert R, Nalbantoglu J, Howell JM, Davies L, Fletcher S, Amalfitano A, Petrof BJ, Kamen A, Massie B, Karpati G. Dystrophin expression in muscle following gene transfer with a fully deleted (''gutted'') adenovirus is markedly improved by trans-acting adenoviral gene products. Hum Gene Ther 2001; 12:1741-1755.

104. Pastore L, Morral N, Zhou H, Garcia R, Parks RJ, Kochanek S, Graham FL, Lee B, Beaudet AL. Use of a liver-specific promoter reduces immune response to the transgene in adeno-viral vectors. Hum Gene Ther 1999; 10:1773-1781.

105. Mitani K, Graham FL, Caskey CT, Kochanek S. Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. Proc Natl Acad Sci USA 1995; 92: 3854-3858.

106. Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL. A helper-dependent adenovirus vector system: Removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA 1996; 93:13565-13570.

107. Morral N, Parks RJ, Zhou H, Langston C, Schiedner G, Qui-nones J, Graham FL, Kochanek S, Beaudet AL. High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha 1-antitrypsin with negligible toxicity. Hum Gene Ther 1998; 9:2709-2716.

108. Morral N, O'Neal WK, Rice K, Leland MM, Piedra PA, Agui-lar-Cordova E, Carey KD, Beaudet AL, Langston C. Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons. Hum Gene Ther 2002; 13:143-154.

109. Ehrhardt A, Kay MA. A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo. Blood 2002; 99:3923-3930.

110. Kim IH, Jozkowicz A, Piedra PA, Oka K, Chan L. Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci USA 2001; 98:13282-13287.

111. Smith TA, White BD, Gardner JM, Kaleko M, McClelland A. Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector. Gene Ther 1996; 3:496-502.

112. Dong JY, Wang D, Van Ginkel FW, Pascual DW, Frizzell RA. Systematic analysis of repeated gene delivery into animal lungs with a recombinant adenovirus vector. Hum Gene Ther 1996; 7:319-331.

113. Kagami H, Atkinson JC, Michalek SM, Handelman B, Yu S, Baum BJ, O'Connell B. Repetitive adenovirus administration to the parotid gland: Role of immunological barriers and induction of oral tolerance. Hum Gene Ther 1998; 9:305-313.

114. Gall J, Kass-Eisler A, Leinwand L, Falck-Pedersen E. Adeno-virus type 5 and 7 capsid chimera: Fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes. J Virol 1996; 70:2116-2123.

115. Gall JG, Crystal RG, Falck-Pedersen E. Construction and characterization of hexon-chimeric adenoviruses: Specification of adenovirus serotype. J Virol 1998; 72:10260-10264.

Wickham TJ. Targeting adenovirus. Gene Ther 2000; 7: 110-114.

Einfeld DA, Brough DE, Roelvink PW, Kovesdi I, Wickham TJ. Construction of a pseudoreceptor that mediates transduction by adenoviruses expressing a ligand in fiber or penton base. J Virol 1999; 73:9130-9136.

Kaneko S, Hallenbeck P, Kotani T, Nakabayashi H, McGarrity G, Tamaoki T, Anderson WF, Chiang YL. Adenovirus-me-diated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res 1995; 55:5283-5287. Rothmann T, Katus HA, Hartong R, Periicaudet M, Franz WM. Heart muscle-specific gene expression using replication defective recombinant adenovirus. Gene Ther 1996; 3: 919-926.

Dematteo RP, McClane SJ, Fisher K, Yeh H, Chu G, Burke C, Raper SE. Engineering tissue-specific expression of a recombinant adenovirus: Selective transgene transcription in the pancreas using the amylase promoter. J Surg Res 1997; 72: 155-161.

Stevenson SC, Rollence M, Marshall-Neff J, McClelland A. Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein. J Virol 1997; 71: 4782-4790.

Krasnykh VN, Mikheeva GV, Douglas JT, Curiel DT. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol 1996; 70:6839-6846. Chillon M, Bosch A, Zabner J, Law L, Armentano D, Welsh MJ, Davidson BL. Group D adenoviruses infect primary central nervous system cells more efficiently than those from group C. J Virol 1999; 73:2537-2540. HavengaMJ, Lemckert AA, Ophorst OJ, van Meijer M, Germ-eraad WT, Grimbergen J, van Den Doel MA, Vogels R, van Deutekom J, Janson AA, de Bruijn JD, Uytdehaag F, Quax PH, Logtenberg T, Mehtali M, Bout A. Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. J Virol 2002; 76:4612-4620. Roelvink PW, Mi LG, Einfeld DA, Kovesdi I, Wickham TJ. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. Science 1999; 286:1568-1571.

Bouri K, Feero WG, Myerburg MM, Wickham TJ, Kovesdi I, Hoffman EP, Clemens PR. Polylysine modification of adenoviral fiber protein enhances muscle cell transduction. Hum Gene Ther 1999; 10:1633-1640.

Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G, Belousova N, Curiel DT. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706-9713.

Kibbe MR, Murdock A, Wickham T, Lizonova A, Kovesdi I, Nie S, Shears L, Billiar TR, Tzeng E. Optimizing cardiovascular gene therapy: Increased vascular gene transfer with modified adenoviral vectors. Arch Surg 2000; 135:191-197. Wickham TJ, Tzeng E, Shears LL, Roelvink PW, Li Y, Lee GM, Brough DE, Lizonova A, Kovesdi I. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol 1997; 71:8221-8229. Miller CR, Buchsbaum DJ, Reynolds PN, Douglas JT, Gillespie GY, Mayo MS, Raben D, Curiel DT. Differential susceptibility of primary and established human glioma cells to adeno-virus infection: Targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res 1998; 58:5738-5748.

Wickham TJ, Haskard D, Segal D, Kovesdi I. Targeting endo-thelium for gene therapy via receptors up-regulated during an-giogenesis and inflammation. Cancer Immunol Immunother 1997; 45:149-151.

132. Alemany R, Suzuki K, Curiel DT. Blood clearance rates of adenovirus type 5 in mice. J Gen Virol 2000; 81:2605-2609.

133. Crystal RG, Harvey BG, Wisnivesky JP, O'Donoghue KA, Chu KW, Maroni J, Muscat JC, Pippo AL, Wright CE, Kaner RJ, Leopold PL, Kessler PD, Rasmussen HS, Rosengart TK, Hollmann C. Analysis of risk factors for local delivery of low-and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions. Hum Gene Ther 2002; 13:65-100.

134. Harvey BG, Maroni J, O'Donoghue KA, Chu KW, Muscat JC, Pippo AL, Wright CE, Hollmann C, Wisnivesky JP, Kessler PD, Rasmussen HS, Rosengart TK, Crystal RG. Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Hum Gene Ther 2002; 13:15-63.

135. Raper SE, Yudkoff M, Chirmule N, Gao GP, Nunes F, Haskal ZJ, Furth EE, Propert KJ, Robinson MB, Magosin S, Simoes H, Speicher L, Hughes J, Tazelaar J, Wivel NA, Wilson JM, Batshaw ML. A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamy-lase deficiency. Hum Gene Ther 2002; 13:163-175.

136. Lieber A, He CY, Meuse L, Schowalter D, Kirillova I, Winther B, Kay MA. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol 1997; 71:8798-8807.

137. Morrissey RE, Horvath C, Snyder EA, Patrick J, MacDonald JS. Rodent nonclinical safety evaluation studies of SCH 58500, an adenoviral vector for the p53 gene. Toxicol Sci 2002; 65:266-275.

138. Gallo-Penn AM, Shirley PS, Andrews JL, Tinlin S, Webster S, Cameron C, Hough C, Notley C, Lillicrap D, Kaleko M, Connelly S. Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs. Blood 2001; 97:107-113.

139. Crystal RG, McElvaney NG, Rosenfeld MA, Chu CS, Mas-trangeli A, Hay JG, Brody SL, Jaffe HA, Eissa NT, Danel C. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibro-sis. Nat Genet 1994; 8:42-51.

140. Harvey BG, Leopold PL, Hackett NR, Grasso TM, Williams PM, Tucker AL, Kaner RJ, Ferris B, Gonda I, Sweeney TD, Ramalingam R, Kovesdi I, Shak S, Crystal RG. Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus. J Clin Invest 1999; 104:1245-1255.

141. Harvey BG, Hackett NR, El Sawy T, Rosengart TK, Hirschow-itz EA, Lieberman MD, Lesser ML, Crystal RG. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. J Virol 1999; 73:6729-6742.

142. Rosengart TK, Lee LY, Patel SR, Sanborn TA, Parikh M, Bergman GW, Hachamovitch R, Szulc M, Kligfield PD, Okin PM, Hahn RT, Devereux RB, Post MR, Hackett NR, Foster T, Grasso TM, Lesser ML, Isom OW, Crystal RG. Angiogene-sis gene therapy: Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999; 100:468-474.

143. Rosengart TK, Lee LY, Patel SR, Kligfield PD, Okin PM, Hackett NR, Isom OW, Crystal RG. Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann Surg 1999; 230:466-470.

144. Harvey BG, Worgall S, Ely S, Leopold PL, Crystal RG. Cellular immune responses of healthy individuals to intradermal administration of an E1-E3-adenovirus gene transfer vector. Hum Gene Ther 1999; 10:2823-2837.

145. Bilbao G, Feng M, Rancourt C, Jackson WHJ, Curiel DT. Adenoviral/retroviral vector chimeras: A novel strategy to achieve high-efficiency stable transduction in vivo. FASEB J 1997; 11:624-634.

146. Ramsey WJ, Caplen NJ, Li Q, Higginbotham JN, Shah M, Blaese RM. Adenovirus vectors as transcomplementing templates for the production of replication defective retroviral vectors. Biochem Biophys Res Commun 1998; 246:912-919.

147. Fisher KJ, Kelley WM, Burda JF, Wilson JM. A novel adeno-virus-adeno-associated virus hybrid vector that displays efficient rescue and delivery of the AAV genome. Hum Gene Ther 1996; 7:2079-2087.

148. Gao GP, Qu G, Faust LZ, Engdahl RK, Xiao W, Hughes JV, Zoltick PW, Wilson JM. High-titer adeno-associated viral vectors from a Rep/Cap cell line and hybrid shuttle virus. Hum Gene Ther 1998; 9:2353-2362.

149. Labow D, Lee S, Ginsberg RJ, Crystal RG, Korst RJ. Adenovirus vector-mediated gene transfer to regional lymph nodes. Hum Gene Ther 2000; 11:759-769.

150. He Z, Wlazlo AP, Kowalczyk DW, Cheng J, Xiang ZQ, Giles-Davis W, Ertl HC. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. Virology 2000; 270:146-161.

151. Schadeck EB, Partidos CD, Fooks AR, Obeid OE, Wilkinson GW, Stephenson JR, Steward MW. CTL epitopes identified with a defective recombinant adenovirus expressing measles virus nucleoprotein and evaluation of their protective capacity in mice. Virus Res 1999; 65:75-86.

152. Zolla-Pazner S, Lubeck M, Xu S, Burda S, Natuk RJ, Sinangil F, Steimer K, Gallo RC, Eichberg JW, Matthews T, Robert-Guroff M. Induction of neutralizing antibodies to T-cell line—Adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees. J Virol 1998; 72:1052-1059.

153. Rodrigues EG, Zavala F, Nussenzweig RS, Wilson JM, Tsuji M. Efficient induction of protective anti-malaria immunity by recombinant adenovirus. Vaccine 1998; 16:1812-1817.

154. Makimura M, Miyake S, Akino N, Takamori K, Matsuura Y, Miyamura T, Saito I. Induction of antibodies against structural proteins of hepatitis C virus in mice using recombinant adenovirus. Vaccine 1996; 14:28-36.

155. Xiang ZQ, Yang Y, Wilson JM, Ertl HC. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology 1996; 219:220-227.

156. Cohen CJ, Xiang ZQ, Gao GP, Ertl HC, Wilson JM, Bergelson JM. Chimpanzee adenovirus CV-68 adapted as a gene delivery vector interacts with the coxsackievirus and adenovirus receptor. J Gen Virol 2002; 83:151-155.

157. Xiang Z, Gao G, Reyes-Sandoval A, Cohen CJ, Li Y, Bergelson JM, Wilson JM, Ertl HC. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol 2002; 76:2667-2675.

158. Mittal SK, Prevec L, Graham FL, Babiuk LA. Development of a bovine adenovirus type 3-based expression vector. J Gen Virol 1995; 76:93-102.

159. Fallaux FJ, Bout A, van der Velde I, van den Wollenberg DJ, Hehir KM, Keegan J, Auger C, Cramer SJ, van Ormondt H, van der Eb AJ, Valerio D, Hoeben RC. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 1998; 9:1909-1917.

160. Magovern CJ, Mack CA, Zhang J, Rosengart TK, Isom OW, Crystal RG. Regional angiogenesis induced in nonischemic tissue by an adenoviral vector expressing vascular endothelial growth factor. Hum Gene Ther 1997; 8:215-227.

161. Fallaux FJ, Kranenburg O, Cramer SJ, Houweling A, van Ormondt H, Hoeben RC, van der Eb AJ. Characterization of 911: A new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum Gene Ther 1996; 7: 215-222.

162. Wang Q, Jia XC, Finer MH. A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal gene-region deletions. Gene Ther 1995; 2:775-783.

163. Yeh P, Dedieu JF, Orsini C, Vigne E, Denefle P, Perricaudet M. Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit. J Virol 1996; 70:559-565.

164. Krougliak V, Graham FL. Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants. Hum Gene Ther 1995; 6:1575-1586.

165. Langer SJ, Schaack J. 293 Cell lines that inducibly express high levels of adenovirus type 5 precursor terminal protein. Virology 1996; 221:172-179.

166. Amalfitano A, Chamberlain JS. Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: Implications for gene therapy. Gene Ther 1997; 4:258-263.

167. Zhou H, O'Neal W, Morral N, Beaudet AL. Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted. J Virol 1996; 70: 7030-7038.

168. Zhou H, Beaudet AL. A new vector system with inducible E2a cell line for production of higher titer and safer adenoviral vectors. Virology 2000; 275:348-357.

169. Hardy S, Kitamura M, Harris-Stansil T, Dai Y, Phipps ML. Construction of adenovirus vectors through Cre-lox recombination. J Virol 1997; 71:1842-1849.

170. Rogers BE, Douglas JT, Ahlem C, Buchsbaum DJ, Frincke J, Curiel DT. Use of a novel cross-linking method to modify adenovirus tropism. Gene Ther 1997; 4:1387-1392.

171. Goldman CK, Rogers BE, Douglas JT, Sosnowski BA, Ying W, Siegal GP, Baird A, Campain JA, Curiel DT. Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Res 1997; 57:1447-1451.

172. Wickham TJ, Segal DM, Roelvink PW, Carrion ME, Lizonova A, Lee GM, Kovesdi I. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J Virol 1996; 70:6831-6838.

173. Wickham TJ, Roelvink PW, Brough DE, Kovesdi I. Adenovi-rus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat Biotechnol 1996; 14:1570-1573.

174. Roelvink PW, Kovesdi I, Wickham TJ. Comparative analysis of adenovirus fiber-cell interaction: Adenovirus type 2 (Ad2) and Ad9 utilize the same cellular fiber receptor but use different binding strategies for attachment. J Virol 1996; 70: 7614-7621.

Your Heart and Nutrition

Your Heart and Nutrition

Prevention is better than a cure. Learn how to cherish your heart by taking the necessary means to keep it pumping healthily and steadily through your life.

Get My Free Ebook

Post a comment